Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 370.22M | 388.31M | 538.65M | 472.17M | 470.50M | 166.32M |
| Gross Profit | -32.36M | -67.25M | -65.09M | -197.46M | -92.76M | -17.27M |
| EBITDA | -153.23M | -194.46M | -172.58M | -355.51M | -356.26M | -229.19M |
| Net Income | -437.94M | -443.22M | -373.09M | -541.40M | -816.59M | -583.26M |
Balance Sheet | ||||||
| Total Assets | 5.77B | 5.91B | 5.24B | 6.08B | 6.66B | 5.90B |
| Cash, Cash Equivalents and Short-Term Investments | 170.03M | 337.12M | 49.23M | 136.06M | 136.09M | 424.83M |
| Total Debt | 3.23B | 3.21B | 2.64B | 2.85B | 2.48B | 2.21B |
| Total Liabilities | 3.95B | 4.01B | 3.37B | 3.84B | 8.08B | 6.52B |
| Stockholders Equity | 1.54B | 1.65B | 1.60B | 1.69B | -1.56B | -678.14M |
Cash Flow | ||||||
| Free Cash Flow | 100.47M | -500.12M | 18.11M | -175.66M | -584.24M | -915.43M |
| Operating Cash Flow | -67.57M | -185.96M | 201.85M | -93.64M | 45.87M | -51.85M |
| Investing Cash Flow | -229.03M | -668.09M | -182.34M | -100.33M | -945.04M | -851.51M |
| Financing Cash Flow | 355.09M | 1.02B | -105.43M | 184.37M | 505.06M | 1.17B |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$384.46M | 4.98 | 4.28% | 7.10% | -2.88% | -22.83% | |
71 Outperform | HK$635.35M | 3.30 | 5.29% | 9.14% | 0.47% | 50.46% | |
66 Neutral | HK$1.48B | 14.78 | 20.47% | 4.37% | -3.56% | -17.45% | |
62 Neutral | HK$7.73B | 17.43 | 4.98% | ― | -13.92% | -36.32% | |
54 Neutral | HK$258.69M | -1.35 | -8.40% | 3.16% | -21.31% | -149.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | HK$1.06B | -5.57 | -27.48% | ― | -21.84% | -20.73% |
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Group has announced a leadership reshuffle, with president Fu Xiao stepping down from the role effective 12 January 2026 as part of normal succession planning, while remaining an executive director and becoming an adviser to the company. The board has appointed Jiang Wei, previously head of the Group’s core AI business and a key figure in advancing its AI-driven oncology diagnosis and treatment capabilities, as the new president, tasking him with integrating the Group’s medical, data and AI strengths, focusing on its core oncology care operations, and accelerating international expansion to consolidate its leading position in AI-enabled cancer care.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. announced that the proton therapy center at its subsidiary Guangzhou Concord Cancer Center has been in official operation for one year as of 16 December 2024, with all four treatment rooms now in use and key operational indicators performing well. The center has delivered proton therapy to 550 patients, treating over 80 new patients in a single month, and has attracted patients from 31 provincial-level regions in China and more than 20 countries and regions, across an age range of 1 to 91, including completion of China’s first proton therapy for ocular choroidal malignant melanoma in July 2025. This progress strengthens Concord Healthcare’s footprint in precision oncology and enhances its competitiveness in high-end medical services, as the company continues to invest in international collaboration, advanced clinical capabilities, and process optimization to expand access to high-quality proton therapy for cancer patients.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. announced that its subsidiary, Guangzhou Concord Cancer Center, has been approved to be included in the list of designated medical institutions under the Measure of Using Hong Kong Registered Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area. This approval allows the company to import and utilize advanced oncology drugs and medical devices from Hong Kong and Macau, which are not yet available in Mainland China. This strategic move is expected to expand the company’s business scope, enhance its competitive advantage in oncology healthcare, and improve cancer treatment standards by integrating international medical resources.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. announced the results of its 2025 Extraordinary General Meeting (EGM), where a special resolution was passed to abolish the Supervisory Committee. The audit committee of the Board will now assume the responsibilities of the Supervisory Committee. This decision reflects the company’s strategic move to streamline its governance structure, potentially impacting its operational efficiency and stakeholder relations positively.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has announced an extraordinary general meeting (EGM) scheduled for December 5, 2025, to discuss the abolition of the Supervisory Committee and propose amendments to the Articles of Association and procedural rules. This move could streamline the company’s governance structure, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. announced that its controlling shareholder, Beijing Concord, has pledged an additional 35,602,300 H shares to China Credit as security for a loan facility. This move is part of an ongoing strategy to secure obligations under a loan agreement, with the pledged shares now representing approximately 4.54% of the company’s total issued shares. This development may impact the company’s financial strategy and stakeholder interests as it navigates its obligations with China Credit.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.